Cargando…

Multiple oncogenic mutations related to targeted therapy in nasopharyngeal carcinoma

INTRODUCTION: An increasing number of targeted drugs have been tested for the treatment of nasopharyngeal carcinoma (NPC). However, targeted therapy-related oncogenic mutations have not been fully evaluated. This study aimed to detect targeted therapy-related oncogenic mutations in NPC and to determ...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jian-Wei, Qin, Tao, Hong, Shao-Dong, Zhang, Jing, Fang, Wen-Feng, Zhao, Yuan-Yuan, Yang, Yun-Peng, Xue, Cong, Huang, Yan, Zhao, Hong-Yuan, Ma, Yu-Xiang, Hu, Zhi-Huang, Huang, Pei-Yu, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4593383/
https://www.ncbi.nlm.nih.gov/pubmed/25963410
http://dx.doi.org/10.1186/s40880-015-0011-0
_version_ 1782393317115297792
author Zhang, Jian-Wei
Qin, Tao
Hong, Shao-Dong
Zhang, Jing
Fang, Wen-Feng
Zhao, Yuan-Yuan
Yang, Yun-Peng
Xue, Cong
Huang, Yan
Zhao, Hong-Yuan
Ma, Yu-Xiang
Hu, Zhi-Huang
Huang, Pei-Yu
Zhang, Li
author_facet Zhang, Jian-Wei
Qin, Tao
Hong, Shao-Dong
Zhang, Jing
Fang, Wen-Feng
Zhao, Yuan-Yuan
Yang, Yun-Peng
Xue, Cong
Huang, Yan
Zhao, Hong-Yuan
Ma, Yu-Xiang
Hu, Zhi-Huang
Huang, Pei-Yu
Zhang, Li
author_sort Zhang, Jian-Wei
collection PubMed
description INTRODUCTION: An increasing number of targeted drugs have been tested for the treatment of nasopharyngeal carcinoma (NPC). However, targeted therapy-related oncogenic mutations have not been fully evaluated. This study aimed to detect targeted therapy-related oncogenic mutations in NPC and to determine which targeted therapy might be potentially effective in treating NPC. METHODS: By using the SNaPshot assay, a rapid detection method, 19 mutation hotspots in 6 targeted therapy-related oncogenes were examined in 70 NPC patients. The associations between oncogenic mutations and clinicopathologic factors were analyzed. RESULTS: Among 70 patients, 12 (17.1%) had mutations in 5 oncogenes: 7 (10.0%) had v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) mutation, 2 (2.8%) had epidermal growth factor receptor (EGFR) mutation, 1 (1.4%) had phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) mutation, 1 (1.4%) had Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation, and 1 (1.4%) had simultaneous EGFR and v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations. No significant differences were observed between oncogenic mutations and clinicopathologic characteristics. Additionally, these oncogenic mutations were not associated with tumor recurrence and metastasis. CONCLUSIONS: Oncogenic mutations are present in NPC patients. The efficacy of targeted drugs on patients with the related oncogenic mutations requires further validation.
format Online
Article
Text
id pubmed-4593383
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45933832015-10-06 Multiple oncogenic mutations related to targeted therapy in nasopharyngeal carcinoma Zhang, Jian-Wei Qin, Tao Hong, Shao-Dong Zhang, Jing Fang, Wen-Feng Zhao, Yuan-Yuan Yang, Yun-Peng Xue, Cong Huang, Yan Zhao, Hong-Yuan Ma, Yu-Xiang Hu, Zhi-Huang Huang, Pei-Yu Zhang, Li Chin J Cancer Original Article INTRODUCTION: An increasing number of targeted drugs have been tested for the treatment of nasopharyngeal carcinoma (NPC). However, targeted therapy-related oncogenic mutations have not been fully evaluated. This study aimed to detect targeted therapy-related oncogenic mutations in NPC and to determine which targeted therapy might be potentially effective in treating NPC. METHODS: By using the SNaPshot assay, a rapid detection method, 19 mutation hotspots in 6 targeted therapy-related oncogenes were examined in 70 NPC patients. The associations between oncogenic mutations and clinicopathologic factors were analyzed. RESULTS: Among 70 patients, 12 (17.1%) had mutations in 5 oncogenes: 7 (10.0%) had v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) mutation, 2 (2.8%) had epidermal growth factor receptor (EGFR) mutation, 1 (1.4%) had phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) mutation, 1 (1.4%) had Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation, and 1 (1.4%) had simultaneous EGFR and v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations. No significant differences were observed between oncogenic mutations and clinicopathologic characteristics. Additionally, these oncogenic mutations were not associated with tumor recurrence and metastasis. CONCLUSIONS: Oncogenic mutations are present in NPC patients. The efficacy of targeted drugs on patients with the related oncogenic mutations requires further validation. BioMed Central 2015-04-08 /pmc/articles/PMC4593383/ /pubmed/25963410 http://dx.doi.org/10.1186/s40880-015-0011-0 Text en © Zhang et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Original Article
Zhang, Jian-Wei
Qin, Tao
Hong, Shao-Dong
Zhang, Jing
Fang, Wen-Feng
Zhao, Yuan-Yuan
Yang, Yun-Peng
Xue, Cong
Huang, Yan
Zhao, Hong-Yuan
Ma, Yu-Xiang
Hu, Zhi-Huang
Huang, Pei-Yu
Zhang, Li
Multiple oncogenic mutations related to targeted therapy in nasopharyngeal carcinoma
title Multiple oncogenic mutations related to targeted therapy in nasopharyngeal carcinoma
title_full Multiple oncogenic mutations related to targeted therapy in nasopharyngeal carcinoma
title_fullStr Multiple oncogenic mutations related to targeted therapy in nasopharyngeal carcinoma
title_full_unstemmed Multiple oncogenic mutations related to targeted therapy in nasopharyngeal carcinoma
title_short Multiple oncogenic mutations related to targeted therapy in nasopharyngeal carcinoma
title_sort multiple oncogenic mutations related to targeted therapy in nasopharyngeal carcinoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4593383/
https://www.ncbi.nlm.nih.gov/pubmed/25963410
http://dx.doi.org/10.1186/s40880-015-0011-0
work_keys_str_mv AT zhangjianwei multipleoncogenicmutationsrelatedtotargetedtherapyinnasopharyngealcarcinoma
AT qintao multipleoncogenicmutationsrelatedtotargetedtherapyinnasopharyngealcarcinoma
AT hongshaodong multipleoncogenicmutationsrelatedtotargetedtherapyinnasopharyngealcarcinoma
AT zhangjing multipleoncogenicmutationsrelatedtotargetedtherapyinnasopharyngealcarcinoma
AT fangwenfeng multipleoncogenicmutationsrelatedtotargetedtherapyinnasopharyngealcarcinoma
AT zhaoyuanyuan multipleoncogenicmutationsrelatedtotargetedtherapyinnasopharyngealcarcinoma
AT yangyunpeng multipleoncogenicmutationsrelatedtotargetedtherapyinnasopharyngealcarcinoma
AT xuecong multipleoncogenicmutationsrelatedtotargetedtherapyinnasopharyngealcarcinoma
AT huangyan multipleoncogenicmutationsrelatedtotargetedtherapyinnasopharyngealcarcinoma
AT zhaohongyuan multipleoncogenicmutationsrelatedtotargetedtherapyinnasopharyngealcarcinoma
AT mayuxiang multipleoncogenicmutationsrelatedtotargetedtherapyinnasopharyngealcarcinoma
AT huzhihuang multipleoncogenicmutationsrelatedtotargetedtherapyinnasopharyngealcarcinoma
AT huangpeiyu multipleoncogenicmutationsrelatedtotargetedtherapyinnasopharyngealcarcinoma
AT zhangli multipleoncogenicmutationsrelatedtotargetedtherapyinnasopharyngealcarcinoma